Julia Kovacova1, Jaroslav Juracek1, Alexandr Poprach2, Jindrich Kopecky3, Ondrej Fiala4,5, Marek Svoboda2, Pavel Fabian6, Lenka Radova1, Petr Brabec7, Tomas Buchler8, Ondrej Slaby9. 1. Masaryk University, Central European Institute of Technology, Brno, Czech Republic. 2. Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3. Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic. 4. Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic. 5. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 6. Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology Faculty of Medicine, Masaryk University, Brno, Czech Republic. 7. Institute for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. 8. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 9. Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic on.slaby@gmail.com.
Abstract
BACKGROUND/AIM: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified. Copyright
BACKGROUND/AIM: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinomapatients treated with sunitinib was identified. Copyright
Authors: N Pompas-Veganzones; V Sandonis; Alberto Perez-Lanzac; M Beltran; P Beardo; A Juárez; F Vazquez; J M Cozar; J L Alvarez-Ossorio; Marta Sanchez-Carbayo Journal: Tumour Biol Date: 2016-09-03
Authors: George Adrian Calin; Chang-Gong Liu; Cinzia Sevignani; Manuela Ferracin; Nadia Felli; Calin Dan Dumitru; Masayoshi Shimizu; Amelia Cimmino; Simona Zupo; Mariella Dono; Marie L Dell'Aquila; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Florencia Bullrich; Massimo Negrini; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2004-07-29 Impact factor: 11.205
Authors: Julia Kovacova; Jaroslav Juracek; Alexandr Poprach; Tomas Buchler; Jindrich Kopecky; Ondrej Fiala; Marek Svoboda; Ondrej Slaby Journal: Anticancer Res Date: 2018-05 Impact factor: 2.480
Authors: Nikolay Kolesnikov; Emma Hastings; Maria Keays; Olga Melnichuk; Y Amy Tang; Eleanor Williams; Miroslaw Dylag; Natalja Kurbatova; Marco Brandizi; Tony Burdett; Karyn Megy; Ekaterina Pilicheva; Gabriella Rustici; Andrew Tikhonov; Helen Parkinson; Robert Petryszak; Ugis Sarkans; Alvis Brazma Journal: Nucleic Acids Res Date: 2014-10-31 Impact factor: 16.971
Authors: E Rossi; M Fassan; M Aieta; F Zilio; R Celadin; M Borin; A Grassi; L Troiani; U Basso; C Barile; T Sava; C Lanza; L Miatello; A Jirillo; M Rugge; S Indraccolo; M Cristofanilli; A Amadori; R Zamarchi Journal: Br J Cancer Date: 2012-09-06 Impact factor: 7.640